Loss narrows modestly. Dyne Therapeutics reported a loss of $0.76 per share for Q4 2025, narrower than the consensus estimate of a $0.76 loss. The pre-revenue biotech posted no revenue for the quarter, consistent with its clinical-stage profile. Shares surged 19.0% on the results, adding $467 million in market value to reach $2.92 billion.
Cash burn remains elevated. Operating cash flow was negative $111.8 million for the quarter, with free cash flow at negative $112.3 million after $484,000 in capital expenditures. The company closed the quarter with $893.4 million in cash and equivalents against $169.2 million in total debt, providing a net cash position of $724.2 million. Research and development expenses totaled $95.4 million, representing 82% of the $116.1 million operating loss. Working capital stood at $1.08 billion, offering runway as the company advances its FORCE platform for muscle disease therapies.
Sequential improvement continues. The Q4 loss of $0.73 per share marks the fourth consecutive quarter of narrowing losses, improving from $0.76 in Q3 2025, $0.97 in Q2 2025, and $1.05 in Q1 2025. The company’s EBITDA loss of $108.2 million reflects the capital-intensive nature of clinical-stage drug development. With stockholders’ equity of $972.1 million supporting operations, the trajectory suggests improving operational efficiency as programs mature.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.